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Time to perform 7 clearly pre-specified tasks was recorded by trained observers 
using a stopwatch. Time of day measurements for subject time in GP surgery and 
vaccination room as well as consumables usage was collected. Time for tasks before 
vaccination day was obtained from opinion. A total 123 processes were observed 
(approximately 20 by site, equally distributed across visits 1 to 4). Analyses were 
run by site and pooled across sites using a random intercept model. Published 
2014 PSSRU data were used to transfer HCP time into cost. Results: Mean HCP 
time for a vaccination process (including a mean 2.75 vaccine doses) was 9.5min 
(95% CI: 7.7-11.3); site range: 7.0-11.3min. Associated cost (90% practice nurse, 10% 
support staff) was £6.2; range: £4.7-£7.7. Mean time for a single oral and intramus-
cular vaccine administration was 1.0 and 0.4min, respectively. Mean time for a 
single vaccine reconstitution was 0.8min. Mean time in GP surgery was 23.9min 
(95% CI: 19.2-28.5), of which 8.4min in vaccination room (95% CI: 5.5-11.2). When 
including average supplies cost (£0.27), as well as an estimated 10.1 minutes per 
vaccination process prior to vaccination day (£5.5), total estimated cost per visit 
was £12.0. ConClusions: Paediatric vaccination requires substantial resources, 
including staff, facility, and parental time. Potential changes in the vaccination 
schedule would have an impact on associated time and cost and the vaccination 
unit’s capacity to managing subjects.
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ce1
Basal insulin Regimens: systematic Review, netwoRk meta-analysis, 
and cost - utility analysis foR the national institute foR health 
and caRe excellence (nice) clinical guideline on type 1 diaBetes 
mellitus in adults
Dawoud D1, Fenu E1, Wonderling D1, O’Mahony R1, Pursey N1, Cobb J1, Amiel SA2,  
Higgins B3
1National Clinical Guideline Centre, Royal College of Physicians (on behalf of the guideline 
development group), London, UK, 2King’s College London, London, UK, 3Newcastle upon Tyne 
Hospitals NHS Trust, Newcastle, UK
objeCtives: To assess the clinical and cost-effectiveness of basal insulin regimens 
for adults with type 1 diabetes mellitus (T1DM), from the English National Health 
Service (NHS) perspective, and inform NICE recommendation regarding optimal 
choice of basal insulin. Methods: We considered seven daily insulin regimens: 
neutral protamine hagedorn (NPH) (once (od), twice (bid) and four-times daily 
(qid)), detemir (od and bid), glargine (od) and degludec (od). A systematic review of 
randomised controlled trials (RCTs) published in Medline, Embase and Cochrane 
databases to August 2014 was undertaken. Relative effectiveness was assessed 
using Bayesian network meta-analysis (NMA) undertaken in WinBUGs. Two out-
comes were analysed: change in haemoglobin A1c (HbA1c) and rate of severe/major 
hypoglycaemia. The cost-utility analysis (CUA) was undertaken using the IMS-CORE 
Diabetes Model (IMS-CDM), following NICE reference case (lifetime time horizon, 
3.5% discount rate for both costs and QALYs (quality-adjusted life-years), net 
monetary benefit (NMB) calculated using a threshold of £20,000 per QALY gained). 
Sensitivity analyses were performed; including changing insulin dose, discount rate 
and cost of hypoglycaemic events. Results: Twenty eight RCTs were included in 
the NMA. The mean change in HbA1c ranged from -0.48% (SE= 0.10) for detemir-(bid) 
to –0.01% (SE= 0.17) for NPH-(qid). Mean rate of severe/major hypoglycaemia ranged 
from 29 (95%CI: 0.00 to 39.76) to 35 (95%CI: 0.00 to 46.73) events/100 person-years. 
The CUA showed that detemir-(bid) had the highest mean QALY-gain (11.09) and 
NMB (£181,456) per patient. Insulin glargine-(od) ranked second. Insulin degludec-
(od) was the most costly, with the highest treatment cost (£7,169). The optimal 
choice was robust to all changes except when high doses of detemir-(bid) were 
assumed (> 30% increment compared to other regimens); where glargine-(od) ranked 
first. ConClusions: Insulin detemir administered twice daily was the optimal 
basal regimen for adults with T1DM from the English NHS perspective; providing 
the highest QALY gain and NMB among the regimens considered.
ce2
a cost-effectiveness analysis of novel oRal anticoagulants foR 
pRimaRy pRevention of venous thRomBoemBolic disease
Bryden P1, Welton NJ1, Thom H1, Sterne J1, Bodalia P2, Davies P1, López-López J1, Okoli GN1, 
Caldwell DM1, Dias S1, Eaton D3, Higgins J1, Salisbury C1, Savovic J1, Sofat R2,  
Stephens-Boal A4, Hingorani A2, Hollingworth W1
1University of Bristol, Bristol, UK, 2University College London, London, UK, 3Anticoagulation 
Europe, Kent, UK, 4Thrombosis UK, Llanwrda, UK
objeCtives: The annual incidence of venous thromboembolic (VTE) disease in 
Europe is 183 per 100,000. If preventative measures are not taken one in three surgi-
cal patients can experience a VTE. This study estimated the cost-effectiveness of 
novel oral anticoagulants in two primary prevention populations; post hip (THR) 
and post knee (TKR) replacement surgery. Methods: For both TKR and THR popula-
tions, initial consequences (180 days) were modelled using a decision tree, followed 
by a Markov model for long term consequences. We evaluated cost-effectiveness of 
dabigatran, rivaroxaban and apixaban, compared with low molecular weight heparin 
(LMWH). Subjects that experienced a recurrent event were treated with apixaban 
and then received aspirin daily for the remainder of their lives. Model inputs dif-
fered between the two populations. Relative treatment efficacy and safety inputs 
came from network meta-analyses; other model inputs were based on a variety of 
evidence sources. Discounted (3.5%) health and benefits (QALYs) over a lifetime were 
estimated. Results: In the THR population rivaroxaban had the highest incremental 
net monetary benefit of £453 (£-485 to £1,312) versus LMWH at a willingness to pay at 
£20,000 per QALY. Dabigatran and apixaban had a negative incremental net monetary 
benefit; £-1,066 (£-12,127 to £3,191) and £-2,284 (£-11,017 to £2,085) respectively. The 
results of the TKR population followed a similar trend. Rivaroxaban had the highest 
were assumed to be $5 (Minimum-Maximum for Scenario Analysis [Min-Max SA]: 
2-10) and $1, respectively. Both costs and benefits were discounted at 3%. Results: 
Over 42 malaria endemic sub-Saharan countries, vaccination with RTS,S at DTP-
coverage was estimated to avert 7.8 (95%CI:4.2-10.6) and 9.3 (95%CI:4.9-12.7) million 
malaria episodes and 50,198 (95%CI:-7,759-108,565) and 63,114 (95%CI:12,218-
110,465) malaria deaths for a birth cohort vaccinated without and with a 4th dose, 
respectively. The overall incremental cost-effectiveness ratio was estimated to reach 
$232 (Min-Max SA:111-433) and $248 (Min-Max SA:119-462) per disability-adjusted 
life-years averted without and with 4th dose, respectively. ConClusions: The 
potential public health impact of implementing RTS,S in infants is estimated to be 
substantial and likely a cost-effective intervention referring to the WHO willingness-
to-pay threshold. However impact and cost-effectiveness of RTS,S would increase if 
malaria vaccination is given at a later age when a higher efficacy has been reported.
va2
cost-effectiveness analysis of QuadRivalent veRsus tRivalent 
influenza vaccination in geRmany — linking a dynamic 
tRansmission model with health and economic outcomes
Dolk FC1, Eichner M2, Welte R3, Anastassopoulou A3, Van Bellinghen L4, Poulsen Nautrup 
B5, Van Vlaenderen I4, Schmidt-Ott R6, Schwehm M7, Postma M1
1University of Groningen, Groningen, The Netherlands, 2Epimos GmbH, Dusslingen, Germany, 
3GSK, München, Germany, 4CHESS in Health, Ternat, Belgium, 5EAH-Consulting, Aachen, 
Germany, 6GSK, Wavre, Belgium, 7ExploSYS GmbH, Leinfelden-Echterdingen, Germany
objeCtives: Trivalent influenza vaccine (TIV) contains two Influenza A strains, 
but only one of the two B-lineages, resulting in frequent mismatches between vac-
cines and circulating B-lineages during seasonal epidemics. Quadrivalent influ-
enza vaccine (QIV) prevents such mismatches by including both B-lineages. The 
objective of our study was to estimate the cost-effectiveness (CE) of QIV versus TIV 
in Germany by coupling influenza incidence generated by a dynamic individual-
based simulation to health and economic outcomes. Methods: An individual-
based simulation tool (known in the literature as 4FLU) was refined to estimate 
the impact of TIV and QIV on clinical infection incidence per year and age over 20 
calendar years in Germany. Cases were subsequently linked to health and economic 
outcomes. Inputs were gathered from national databases and published literature. 
Vaccination rates reflect the current coverage in Germany; 2014 was used as the 
baseline year for costs. The productivity costs (societal perspective) were calculated 
according to the human capital approach. Costs and effects were discounted at 
3% and 1.5%, respectively. Univariate and probabilistic sensitivity analyses were 
performed. Results: Per 100,000 inhabitants, QIV prevents 6,803 more clinical 
influenza cases and 6.45 more deaths than TIV, accumulated in 20 years. From the 
societal perspective, QIV dominates TIV, with € 1,424,323 of cost savings and 152 
QALYs gained (98 QALYs by preventing clinical cases and 54 QALYs by avoiding 
premature mortality). These results are sensitive to changes in perspective, vacci-
nation coverage, vaccine prices, productivity cost approach and discount rates, yet 
favorable CE remains. ConClusions: Based on our analysis, QIV is expected to be 
cost-effective, or even cost-saving in Germany. Our results are in line with findings 
from other studies using dynamic models and for other settings.
va3
economic evaluation of childRen vaccination fRom 2 to 18 yeaRs of 
age with the live attenuated influenza vaccine compaRed with the 
existing vaccines in the poRtuguese setting
Ferreira J1, Trindade R1, Norte J1, Sackeyfio A2
1Astrazeneca Produtos Farmacêuticos Lda., Lisboa, Portugal, 2AstraZeneca Alderley House, 
Alderley Park, UK
objeCtives: Vaccination is established as one of the most effective methods to 
prevent influenza and reduce the related social and economic burden. The objec-
tives of this study were to estimate the cost-effectiveness ratios of using the live 
attenuated influenza vaccine (LAIV), indicated for children aged 2 to 18 years, 
as well as evaluate the impact of herd immunity in the non-vaccinated popula-
tion. Methods: An adaptable and flexible dynamic transmission model, stratified 
by age, was used to simulate the impact of influenza infection, with a time horizon 
of 5 years. This study was conducted in a payer perspective and was adapted to 
the Portuguese setting, as all data related to demographics and costs belonged to 
Portuguese sources. Results: In the base case scenario, two different childhood 
vaccination policies were compared: use the trivalent influenza vaccine (TIV) cur-
rently in the market or use the LAIV, both for healthy children population. For 
the same number of vaccinated individuals, the LAIV achieved a reduction in the 
incidence of influenza and in the number of deaths due to influenza mostly among 
the elderly, when compared with the results obtained with TIV. The incremental 
cost-effectiveness ratios obtained were 7,448 and 8,527€ /QALY, for a vaccination 
coverage of 25 and 75%, respectively. The net monetary benefit obtained was posi-
tive. ConClusions: The results showed that the strategy for influenza vaccination 
using LAIV in children is cost-effective as it reduces the costs related to influenza 
infection and has a positive impact in the Portuguese healthcare from direct and 
indirect protection in the community.
va4
cost of paediatRic vaccine administRation in the united kingdom 
(uk): a time and motion (t&m) study
Mokiou S1, de Cock E2, Standaert B3
1UBC: An Express Scripts Company, London, UK, 2United BioSource Corporation, Barcelona, Spain, 
3GSK Vaccines, Wavre, Belgium
objeCtives: Few studies have estimated time and associated cost related to a pae-
diatric vaccination visit. Time and Motion (T&M) methodology is suitable to collect 
efficiency-related outcomes. The aim was to quantify active healthcare professional 
(HCP) time and associated costs of a single vaccination process administered in a 
paediatric population in the UK. Methods: Paediatric vaccination processes were 
observed in 6 General Practitioner (GP) surgeries across UK in children 2-14 months. 
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in FH was undertaken in 2004-2014 reviewing FH registries, PubMed and refer-
ence citations. Papers were assessed for bias using Newcastle-Ottawa scale. The 
literature-based FH relative risk (RR) was calculated. To validate the RR, a 10-year 
baseline risk of CV events was estimated for Rutherford-2 clinical trial population. 
The RR was used to adjust D’Agostino 2008 (primary prevention) and Wilson 2012 
(secondary prevention) baseline risk estimates. Sensitivity analyses varying patient 
characteristics were conducted. Results: Out of 796 identified publications, 14 
manuscripts met inclusion criteria. Danish population-based study (Benn 2012) 
showed the least risk of bias by directly comparing FH and non-FH populations in 
the same study and evaluating both fatal and non-fatal CV events. Subjects treated 
and untreated with lipid lowering therapy had odds ratio for coronary artery disease 
at 10.3 (95% CI: 7.8-13.8) and 13.2 (95% CI: 10.0 – 17.4), respectively. The FH RR of 
5.9 (5.0-6.9) and rate ratio of 7.1 (5.7-8.7) was calculated by pooling statin and no-
statin groups. Pooling the treated and untreated groups was introduced to mimic 
real world, accounting for the mix of primary and secondary prevention patients 
as well as different treatment paradigms. Combining the derived RR with the risk 
predicted by equations yielded a 55% 10-year baseline risk for Rutherford-2 FH 
patients. Patient characteristics such as proportion of patients receiving second-
ary prevention or age had an impact on estimated risk. ConClusions: Benn 2012 
provides estimates of increased CV risk for FH with the least bias. Estimated risk 
for Rutheford-2 patients is plausible for this high risk population. The derived RR 
seems acceptable for the use in economic modeling.
cv2
suRvival and Rehospitalization afteR a fiRst hospitalization foR 
heaRt failuRe: a nationwide population-Based cohoRt study using 
the fRench egB dataBase
Bonnet C1, Millot I1, Achouba A2, Czekala M2, Chauny J2, Thonnelier C2, Husson-Robert B3, 
Cottin Y4
1ORS Bourgogne Franche-Comté, Dijon, France, 2Novartis Pharma SAS, Rueil-Malmaison, France, 
3ORS Bourgogne Franche-Comté, DIJON, France, 4CHU Bocage, Dijon, France
objeCtives: To analyze survival and rehospitalization after a first hospitalization 
for heart failure (HF) in France. Methods: Analysis was based on EGB (“Echantillon 
Généraliste des Bénéficiaires”) database, a permanent random sample (1/97) of the 
French national healthcare insurance system database (SNIIRAM), linked with the 
national hospital discharge summary database (PMSI). Selected patients were adults 
(≥ 18 years) with a first HF hospitalization (ICD-10 codes: I-50/I-110/I-130/I-132) 
over a 3-years period (from 1st January 2009 to 31st December 2011). Patients were 
observed until death or 31stDecember 2013. Results: For analyses, 2,173 patients 
were included. Average age was 79 years (56% ≥ 80 years; 44% < 80 years) and sex 
ratio was close to parity (51% of woman; 49% of men). Average length of stay for 
the first HF hospitalization was 9.2 days (SD= 7.5 days) and 81% of these stays were 
strongly related to “heart failure or circulatory shock” (French DRG code: 05M09). 
The HF management was not optimal, with few cardiologist visits within the year 
prior the first HF hospitalization and low rates of prescription of HF recommended 
drugs. The median survival time was 37 months following the first HF hospitaliza-
tion and median time to rehospitalization was 15 months after the first HF hospi-
talization. The mortality and rehospitalization following the first HF hospitalization 
were both dramatically increased in older patients (≥ 80 years): respectively HR= 2.57 
(95%IC= [2.27-2.92]; p< 0.001) and HR= 1.68 (95%IC 1.51-1.87; p< 0.001). However, these 
events were both reduced in patients who visited a cardiologist during the year prior 
the first HF hospitalization: respectively HR= 0,84 (95%IC= [0.74-0.94]; p= 0.0036) and 
HR= 0.89 (95%IC= [0.80-0.99]; p= 0.0278). No significant difference on mortality or on 
rehospitalization was observed according to sex or treatments. ConClusions: 
Cardiologist visits remain at a very low frequency in this HF population. Better 
referring these patients to cardiologists should consolidate their management and 
thus reduce rehospitalization and mortality.
cv3
the cost and length of stay of hospital emeRgency depaRtment 
visits foR chRonic heaRt failuRe patients in canada
Fischer AA1, Liu N1, Borelli R1, Zaour N2, Barbeau M2
1IMS Brogan, Mississauga, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, 
Canada
objeCtives: More than 600,000 Canadians are afflicted with chronic heart fail-
ure (CHF), which is associated with high hospitalization and mortality rates. The 
objective of this study is to evaluate the mean cost ($CAD) and length of stay (LOS) 
amongst CHF patients treated in emergency departments (ED), stratified by sur-
vival and death outcomes. This abstract builds upon previously presented research 
to evaluate the costs of hospitalization due to CHF in a Canadian acute care set-
ting. Methods: Hospital discharge abstracts recorded between 2009 and 2013 from 
the Canadian Institute for Health Information’s Discharge Abstract Database and 
National Ambulatory Care Reporting System database were analyzed using a ret-
rospective cross-sectional study design. The two databases contain Canadian ED, 
acute care, and same-day surgery discharge abstracts. Discharge abstracts with 
congestive heart failure (ICD-10 code I50.0) recorded as the most responsible rea-
son for ED hospitalization amongst patients aged ≥ 18 were included in the study. 
Discharge abstracts with missing demographics, or absent without leave or against 
medical advice discharge status were excluded from the study. Results: 126,498 
ED discharge abstracts were included, with 99.8% of the visits ending in patient 
survival at discharge. The national mean CHF ED visit cost was $628, with survival 
outcomes incurring $628 and death outcomes incurring $502. The national mean 
CHF ED visit length of stay of was 0.56 days with survival outcomes requiring 0.57 
days and death outcomes requiring 0.16 days. The mean ED visit cost decreased with 
age with 18 to 34, 35 to 64, and 65+ incurring $670, $619, and $629 respectively. In 
contrast, the mean LOS increased with age: 18 to 34, 35 to 64 and 65+ experienced 
0.48, 0.50, and 0.58 days respectively. ConClusions: CHF ED visits are associated 
with significant healthcare cost and time investments, which provide an opportu-
nity for interventions that reduce the healthcare burden.
incremental net monetary benefit of £16 (£-406 to £329) at a willingness to pay of 
£20,000 per QALY. Dabigatran and apixaban had an incremental net monetary ben-
efit; £-320 (£-2,844 to £638) and £-686 (£-2,458 to £266) respectively. ConClusions: 
Rivaroxaban had the highest net monetary benefit at a willingness to pay threshold 
of £20,000 for primary prevention (THR and TKR). However, there was substantial 
uncertainty around these results in both populations.
ce3
a cost effectiveness analysis of nivolumaB compaRed to ipilimumaB 
foR the tReatment of BRaf wild-type advanced melanoma in 
austRalia
Bohensky M1, Pasupathi K1, Gorelik A2, Kim H3, Harrison JP3, Liew D1
1Melbourne University, Parkville, Australia, 2Royal Melbourne Hospital, Parkville, Australia, 
3Bristol-Myers Squibb Australia, Mulgrave, Australia
objeCtives: To evaluate the cost-effectiveness, from an Australian health sys-
tem perspective, of nivolumab versus ipilimumab for treatment of patients with 
previously-untreated, BRAF wild-type (WT) advanced melanoma (AM), comprising 
unresectable and/or metastatic melanoma). Methods: A state-transition Markov 
model with 3 health states (‘Alive, pre-progression’, ‘Alive, post progression’ and 
‘Dead’) and 12-week cycles was constructed to simulate the history of BRAF-WT 
Australian patients with AM. A 5% annual discount rate was applied to costs and 
health measures. A 10-year time horizon was selected to capture the long-term 
survival achieved with immunotherapy agents. For the Nivolumab Group, risks of 
progression and death were based on those observed in the Nivolumab arm of 
study CA209-066 (nivolumab versus dacarbazine). Log-logistic functions were used 
to extrapolate trial data up to 10 years based on AIC and clinical plausibility. For 
the Ipilimumab Group, transition probabilities were derived from applying hazard 
ratios (HRs) to the corresponding transition probabilities in the Nivolumab Group. 
In the absence of head-to-head evidence, HRs were calculated by indirect compari-
son of nivolumab versus ipilimumab using published data. AM management costs 
were estimated by survey of Australian clinicians. Ipilimumab costs were based on 
prices reimbursed under the Pharmaceutical Benefits Scheme (PBS) of Australia.
Nivolumab costs were based on the expected reimbursed price under the PBS per 
course of treatment. Utilities were determined using EQ-5D data from study CA209-
066. Probabilistic sensitivity analyses were undertaken using variations to key input 
parameters. Results: Compared to ipilimumab, nivolumab therapy over 10 years 
would lead to an improvement in survival of 1.58 years and 1.30 QALYs per per-
son, at a (discounted) net cost of AUD$77,119 per person. These equate to ICERs of 
AUD$48,851 per year of life saved and AUD$59,311 per QALY saved. ConClusions: 
Compared with ipilimumab, nivolumab represents a cost-effective means of improv-
ing outcomes among Australian patients with AM.
ce4
assessing the cost-effectiveness of using aclidinium BRomide 400 
µg /foRmoteRol fumaRate dihydRate 12 µg compaRed to aclidinium 
BRomide 400 µg in the management of modeRate to seveRe chRonic 
oBstRuctive pulmonaRy disease
Ramos M1, Haughney J2, Henry N3, Lindner L4, Lamotte M1
1IMS Health, Vilvoorde, Belgium, 2University of Aberdeen, Aberdeen, UK, 3IMS Health, London, UK, 
4AstraZeneca, Barcelona, Spain
objeCtives: Aclidinium/formoterol 400/12 µg (FDC 400/12 µg), is a long-acting mus-
carinic antagonist (LAMA) and a long-acting β 2-agonist (LABA) in a fixed-dose com-
bination used in the management of patients with chronic obstructive pulmonary 
disease (COPD). This study aimed to assess the cost-effectiveness of FDC 400/12 µg 
against the LAMA, aclidinium bromide 400 µg (AB 400 µg). Methods: A 5 health 
state Markov transition model, with monthly cycles, was developed using MS Excel 
to simulate the clinical course of patients with moderate to severe COPD treated with 
FDC 400/12 µg versus AB 400 µg. Health states were based on severity levels defined 
by GOLD 2010 criteria. The analysis was a head to head comparison without step-
up-therapy, from the NHS Scotland perspective, over a 5 year time horizon. Clinical 
data on the initial lung function improvement was provided by a pooled analysis of 
the ACLIFORM and AUGMENT trials. Resource use (management and event costs) and 
utilities were health state specific. Costs and effects were discounted at an annual 
rate of 3.5%. The outcome of the analysis was cost (£) per quality adjusted life year 
(QALY) gained. The analysis included one way and probabilistic sensitivity analyses 
to investigate the impact of parameter variability on model outputs. Results: FDC 
400/12 µg provided marginally higher costs (£41) and more QALYs (0.014), resulting 
in an incremental cost-effectiveness ratio of £2,976. Sensitivity analyses indicated 
results were generally robust to key parameter variation. The main drivers were mean 
baseline FEV1, risk of exacerbation, FEV1 improvement of FDC 400/12 µg and lung 
function decline. The probability of FDC 400/12 µg be cost-effective (using a willing-
ness to pay threshold of £20,000/QALY) versus AB 400 µg was 79%. ConClusions: 
In the Scottish setting, aclidinium/formoterol 400/12 µg can be considered a cost-
effective treatment option in patients with COPD versus aclidinium 400 µg.
caRdiovasculaR disease ReseaRch studies
cv1
the magnitude of incReased caRdiovasculaR (cv) Risk associated 
with familial hypeRcholesteRolemia (fh) foR use in economic 
analyses
Wong B1, Villa G2, Kutikova L2, Kruse G1, Ray KK3, Mata P4, Bruckert E5
1University of Pennsylvania, Philadelphia, PA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 
3School of Public Health, Imperial College London, London, UK, 4Fundación Hipercolesterolemia 
Familiar, Madrid, Spain, 5Hôpital Pitié Salpêtrière, Paris, France
objeCtives: To derive an estimate for increased cardiovascular (CV) risk in familial 
hypercholesterolemia (FH) patients for use in economic analyses. Methods: A 
literature search reporting CV risk, rates, odds or ratios of mortality and morbidity 
